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ABSTRACT
Aim: The purpose of this manuscript was to illustrate the impact of the place in the treatment
sequence on the cost and cost-effectiveness of different biologics for patients with moderate-to-severe
plaque psoriasis.
Materials and methods: We developed a treatment sequence model and focused on seven different
biological treatment options and 840 combinations of treatment sequences. The model converted cost
of treatment to a cost per responder by dividing treatment cost by expected number of patients
achieving PASI100 after 52 weeks of treatment. We used Spanish ex-factory price levels, dosing recom-
mendations and real-world data on drug survival to calculate the treatment costs.
Results: The most cost-effective treatment sequence was brodalumab–risankizumab–guselkumab–ixe-
kizumab, with a cost per responder of e139,281 during the first five years of treatment. In comparison,
if brodalumab was not recommended as first-line therapy, total costs would increase by 7.4% to
e149,616. If brodalumab was not recommended as any of the first four lines of treatment, total costs
would increase by 13.1% to e157,527 relative to the most cost-effective treatment sequence.
Conclusions: A sequential therapy model may improve efficiency in the treatment of psoriasis.
According to our results, brodalumab as the first-line therapy in Spain leads to the most cost-effective
treatment sequence.
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Introduction
Psoriasis is a chronic, relapsing, immune-mediated skin dis-
ease associated with significant clinical morbidity. The most
common type is psoriasis vulgaris, which is characterized by
relapsing thick, scaling plaques that are itchy and sometimes
painful. The prevalence of psoriasis in any given population
ranges from 2% to 3%1, with the majority remaining undiag-
nosed or underserved2. Psoriasis often impacts quality of life,
e.g. a National Psoriasis Foundation Survey found that emo-
tional wellbeing was affected for 88% of psoriasis patients,
and 82% reported adverse effects on their enjoyment of life3.
Around 20% of psoriasis vulgaris patients suffer from moder-
ate-to-severe psoriasis4, which is often defined with the “rule
of ten” (body surface area (BSA)>10 or psoriasis area and
severity index (PASI) >10) and dermatology life quality index
(DLQI) >105.
According to the European Medicines Agency, biologic
therapies are typically indicated for the treatment of adult
patients with moderate-to-severe plaque psoriasis.
Treatments with biologics have significantly decreased the
severity of the disease for patients with moderate-to-severe
psoriasis. Several biological treatments are available, e.g. the
older anti-tumor necrosis factors (TNFs) (adalimumab, etaner-
cept, infliximab, certolizumab pegol), anti-interleukin (IL)-12/
23 (ustekinumab), and the modern biologics anti-IL-17s (bro-
dalumab, secukinumab, ixekizumab), and anti-IL-23s (guselku-
mab, risankizumab, tildrakizumab). A majority of patients
with psoriasis fail their biologic treatment over time due to
loss and lack of efficacy, tolerability and other reasons6,7.
They will use a range of biologics over time, and as treat-
ments have different cost and efficacy outcomes, selecting
the right treatment sequence will have an impact on cost-
effectiveness.
Since several biologics for moderate-to-severe plaque
psoriasis have come to market, decision-makers need more
insight to determine the optimal treatment sequence to
maximize use of limited resources. Typically, health economic
models within psoriasis research do not model treatment
pathways and the order of treatment options. This is also
indicated by recent systematic reviews8,9. A study investi-
gated cost-effectiveness of sequential biologic therapy in the
UK with ixekizumab versus secukinumab as first-line treat-
ment10. They compared two treatment sequences:
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“ixekizumab – ustekinumab – infliximab – best supportive care
(BSC)” versus “secukinumab – ustekinumab – infliximab – BSC”
and found that the ixekizumab treatment sequence provided
slight advantages in cost savings and Quality Adjusted Life
Years (QALY) versus the secukinumab sequence. Another
study investigated biologic treatment sequences by use of a
cost–utility analysis based on 10 years of real-world evidence
from the BioCAPTURE registry in the Netherlands11. They
compared six different consecutive lines of biologic treat-
ments (adalimumab, etanercept and ustekinumab). They did
not find any significant differences among these treatment
sequences in terms of cost-effectiveness.
To date, there are no published treatment sequence anal-
yses in psoriasis comparing both the older biologics as well
as the newer biological treatment options (TNFs, IL-12/23, IL-
17s and IL-23s). The purpose of this analysis was to illustrate
the value and cost-effectiveness for seven different biological
treatment options and numerous different treatment sequen-
ces for patients with moderate-to-severe plaque psoriasis. In
total, 840 different combinations of treatments were ana-
lyzed and ranked from high to low cost-effectiveness.
Methods
To evaluate costs of different biological treatment sequences
for psoriasis, we developed a treatment sequence model
from a Spanish payer perspective with each possible treat-
ment sequence ranked from the most cost-effective to the
least cost-effective, defined as the lowest cost per patient
reaching PASI100.
The model simulated a patient’s course of treatment over
five years, beginning with initiation on first-line biological
therapy. A decision-tree structure was applied with treatment
cycles that cover four weeks each. Patients were assumed to
leave the biological treatments gradually and switch to next-
in-line therapy. This was driven by treatment discontinuation
rates and implied that after each cycle, a patient would
either continue treatment or switch to next-in-line therapy.
This is presented graphically in Figure 1.
Model simulations indicated that a combination of a
maximum of four biological therapies, over a time horizon
of five years, was relevant for the average patient with
moderate-to-severe plaque psoriasis. We therefore limited
the model to evaluating costs associated with treatment of
up to four biological therapies. Over five years, very few
patients would discontinue the fourth-line treatment with
the applied assumptions. Discontinuation was therefore set
to zero following the fourth-line treatment to ensure that no
patients were out of treatment.
The primary analysis was undertaken for seven different
biological treatments. The following therapies were included:
certolizumab pegol, ustekinumab, brodalumab, secukinumab,
ixekizumab, guselkumab, and risankizumab. No biosimilars
were included in the primary analysis, but a sensitivity ana-
lysis was undertaken to analyze the impact of biosimilars in
the choice set, i.e. we included the lowest priced biosimilar
adalimumab as an option.
Model inputs
Drug costs
Treatment costs were calculated for each patient in the
model based on the combination of therapies they received,
the treatment duration for each product in the sequence,
and the cost of therapies. Costs associated with administra-
tion, monitoring and adverse events were not considered in
the model as they comprise less than 2% of the over-
all costs12.
For each biological therapy in the model, the associated
cost was based on Spanish ex-factory price levels, excluding
VAT. Calculations of treatment costs were based on the dos-
ing recommendations in the summaries of product character-
istics (SmPCs) for the different therapies13–20. There was a
distinction between induction and maintenance doses, where
induction was characterized by a period during which the
treatment frequency or dose was higher than normal. We
assumed that all patients would go through induction when
initiating treatment and if they switched treatment.
Figure 1. Illustration of a treatment sequence. The figure presents the model outline. All patients are initiated on first-line therapy at the beginning of the mode.
Afterwards, patients will discontinue gradually based on the discontinuation rates. After discontinuation, patients will start next-in-line therapy.
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Information on drug costs and dosing formulation during
the induction and maintenance periods is summarized in
Table 1.
Discontinuation
It was assumed that patients initiating biological treatments
would discontinue treatments gradually. Discontinuation
could be caused by, for example, loss and lack of efficacy,
tolerability or adverse events requiring patients to terminate
their current therapy6,7.
In this treatment sequence model, the risk of discontinu-
ation was defined by drug survival curves published in Yiu
et al.7 Yiu et al. provided long-term drug survival data on
adalimumab, ustekinumab and secukinumab in patients with
moderate-to-severe psoriasis. The study was based on the
British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR), which is a large,
ongoing pharmacovigilance registry of patients with psoriasis
in the UK and the Republic of Ireland. The study used
Kaplan–Meier’s survival analysis to estimate the drug survival
one and two years after treatment initiation.
For adalimumab, ustekinumab and secukinumab, we con-
verted the two-year drug survival rates to four-week discon-
tinuation rates. Ixekizumab, brodalumab, guselkumab,
risankizumab, and certolizumab pegol were not included in
the study by Yiu et al. In the base case scenario, we there-
fore applied the discontinuation rate of adalimumab to all
anti-TNF therapies, the discontinuation rate of ustekinumab
to all IL-23 therapies, and the discontinuation rate of secuki-
numab to all IL-17 therapies. Furthermore, it was assumed,
contrary to clinical trials, that patients seen in daily clinical
practice did not undergo a washout period prior to initiation
of next-in-line biological therapy. The per-cycle discontinu-
ation rates for each considered therapy are presented in
Table 2.
It takes time to see the full effect of biological treatments,
and the treatment response is usually evaluated after the
first 12–16 weeks. For each therapy, we defined the relevant
evaluation period based on the recommendations in the
SmPCs. If not specified, the induction period in the SmPC
was used. During this evaluation period, patients were
assumed to stay on the treatment regardless of their clinical
response, since the full effects of the treatment were not yet
obtained. This would result in a larger share of patients leav-
ing treatment after evaluation. The length of the evaluation
period is summarized in Table 2.
Cost per responder
The effectiveness of treatments varies greatly across the
investigated therapies. To account for these differences, the
model converted the cost of treatment to a cost per
responder by dividing the treatment cost by the expected
number of patients who responded to the treatment. In the
primary analysis, responders were defined as patients who
achieved PASI100 after 52 weeks of treatment. The share of
patients who achieved PASI100 was based on data from a
published network meta-analysis by Yasmeen et al.21 The













Treatment drug cost (e)
First year Second year
Adalimumab Week 0: 40mg 40 2 874.05 10.93 12,237 11,363
Maintenance: 40mg every 2 weeks
Ustekinumab Weeks 0 and 4: 45mg 45 1 2747.36 61.05 16,484 10,989
Maintenance: 45mg every 12 weeks
Secukinumab Weeks 0–4: 300mg every week 150 2 1143.11 3.81 19,433 14,860
Maintenance: 300mg monthly (every 4 weeks)
Ixekizumab Week 0: 160mg 80 2 2020.00 12.63 18,180 13,130
Weeks 2–12: 80mg every 2 weeks
Maintenance: 80mg every 4 weeks
Brodalumab Weeks 0, 1 and 2: 210mg 210 2 1050.16 2.50 14,702 13,652
Maintenance: 210mg every 2 weeks
Guselkumab Weeks 0 and 4: 100mg 100 1 2536.10 25.36 20,289 15,217
Maintenance: 100mg every 8 weeks
Risankizumab Weeks 0 and 4: 150mg 75 2 3833.49 25.55 22,998 15,332
Maintenance: 150mg every 12 weeks
Certolizumab pegol Weeks 0, 2 and 4: 400mg 200 2 948.00 2.37 14,220 12,324
Maintenance: 400mg every 2 weeks
Posology during the induction period and the maintenance period is based on product resumes. The pack size and the corresponding price were chosen to min-
imize the cost per treatment. Drug costs are Spanish ex-factory price levels, excluding VAT, accessed in May 2020.














Adalimumab 4 1.59% 6.19% 18.8%
Ustekinumab 7 1.00% 6.79% 12.3%
Secukinumab 4 1.00% 6.79% 12.3%
Ixekizumab 4 1.00% 6.79% 12.3%
Brodalumab 4 1.00% 6.79% 12.3%
Guselkumab 4 1.00% 6.79% 12.3%
Risankizumab 4 1.00% 6.79% 12.3%
Certolizumab pegol 4 1.59% 6.19% 18.8%
Discontinuation rates are based on drug survival reported in Yiu et al.7 for
adalimumab, ustekinumab and secukinumab. Ixekizumab, brodalumab, gusel-
kumab, risankizumab, and certolizumab pegol were not included in the study
by Yiu et al. In the base case scenario, we therefore applied the discontinu-
ation rate of adalimumab to all anti-TNF therapies, the discontinuation rate of
ustekinumab to all IL-23 therapies, and the discontinuation rate of secukinu-
mab to all IL-17 therapies. The length of the evaluation period is based on
product resumes, if not specified, the induction period in the product resumes
was used.
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network meta-analysis was based on a total of 28 random-
ized controlled trials, including 9,940 patients, identified
through a systematic literature review on randomized con-
trolled trials and long-term extensions assessing the efficacy
of biologic therapies in adult patients with moderate-to-
severe plaque psoriasis. The analysis included different PASI
outcomes, i.e. PASI75, PASI90, and PASI100. Outcomes were
measured between weeks 40 and 64. These estimates are
presented in Table 3.
Results
The analysis included 840 different combinations of treat-
ments. The cost per responder was calculated for each com-
bination and ranked from high to low cost-effectiveness.
Most cost-effective treatment sequences
Table 4 presents the top five most cost-effective treatment
sequences for patients with moderate-to-severe plaque psor-
iasis. The most cost-effective treatment sequence was broda-
lumab–risankizumab–guselkumab–ixekizumab
(BRO–RIS–GUS–IXE), with a cost per responder of e139,283
during the first five years of treatment.
The table shows that brodalumab followed by risankizu-
mab was the most cost-effective choice for first- and second-
line therapies in all the top five most cost-effective treatment
sequences. Moreover, the table indicates that it was optimal
to include guselkumab or ixekizumab as a third-line treat-
ment, and ixekizumab, guselkumab, ustekinumab, secukinu-
mab or certolizumab pegol as a fourth-line treatment. The
last column of the table shows that the cost per responder
varied only modestly across the top five most cost-effective
treatment sequences during the first five years of treatment.
When a full analysis of the 840 different treatment
sequences was conducted, brodalumab was chosen as the
first-line therapy in all the top 81 most cost-effective treat-
ment sequences. This is because brodalumab has a high effi-
cacy rate and a per-patient cost that is close to the median
cost of all the available alternatives. Another important factor
when determining the most cost-effective choice of first-line
therapy is the higher cost of treatment during the induction
period. By comparing the cost of treatment using brodalu-
mab during the first year with the cost of treatment using
brodalumab in future years, as presented in Table 1, it was
seen that the induction period implied an added cost of
e1,050, corresponding to a 7.7% increase. In contrast to this,
the incremental cost of treatment during the first year with
risankizumab was e7,667 higher as compared with the cost
of treatment using risankizumab in future years, correspond-
ing to a 50% increase.
To analyze the importance of introducing a new cost-
effective first-line therapy, it is potentially more relevant to
compare the most cost-effective treatment sequence with (1)
a cost-effective treatment sequence in a scenario in which
brodalumab is not recommended as first-line therapy and (2)
a cost-effective treatment sequence in a scenario in which
brodalumab is not recommended as any of the first four
lines of treatment. These results are presented in Table 5.
The table demonstrated that if brodalumab was not recom-
mended as first-line treatment, risankizumab took over as the
most cost-effective choice of first-line therapy. Of the 840 possible
combinations of therapies,
Table 3. PASI response rates.
Treatment 52-week NMA
PASI75 PASI90 PASI100
Adalimumab 68.9% 49.7% 25.6%
Ustekinumab 76.3% 58.5% 33.2%
Secukinumab 81.9% 66.0% 40.6%
Ixekizumab 85.0% 70.5% 45.6%
Brodalumab 89.1% 76.8% 53.3%
Guselkumab 89.1% 76.8% 53.3%
Risankizumab 91.5% 80.9% 58.9%
Certolizumab pegol 71.1% 52.2% 27.6%
PASI scores are based on estimates published by Yasmeen et al.21 and repre-
sent the share of patients who as a minimum achieved the specific PASI score
between weeks 40 and 64.
Table 4. Baseline results from the treatment sequence model: top five cost-effective treatment sequences (in e).
Rank 1st line 2nd line 3rd line 4th line Cost 1st line Cost 2nd line Cost 3rd line Cost 4th line Total cost
1 Brodalumab Risankizumab Guselkumab Ixekizumab 96,588 34,133 7,285 1,277 139,283
2 Brodalumab Risankizumab Ixekizumab Guselkumab 96,588 34,133 7,504 1,226 139,451
3 Brodalumab Risankizumab Guselkumab Ustekinumab 96,588 34,133 7,285 1,530 139,536
4 Brodalumab Risankizumab Guselkumab Secukinumab 96,588 34,133 7,285 1,560 139,565
5 Brodalumab Risankizumab Guselkumab Certolizumab pegol 96,588 34,133 7,285 1,724 139,730
The table presents the top five cost-effective treatment sequences among the 840 combinations of possible treatments. The cost represents the aggregated
costs during the five-year time horizon. The cost of first-, second-, third- and fourth-line therapy represents the aggregated cost per responder associated with
treatment with the therapy in the specific line of treatment.
Table 5. Cost-effective treatment sequences if brodalumab is not recommended as first-line therapy or any of the first four lines of therapy compared to rank 1
where brodalumab is allowed as first-line therapy (in e).
Rank 1st line 2nd line 3rd line 4th line Cost 1st line Cost 2nd line Cost 3rd line Cost 4th line Total cost
1 Brodalumab Risankizumab Guselkumab Ixekizumab 96,588 34,133 7,285 1,277 139,283
82 Risankizumab Brodalumab Guselkumab Ixekizumab 112,931 28,124 7,285 1,277 149,616
171 Risankizumab Ixekizumab Guselkumab Ustekinumab 112,931 35,784 7,285 1,530 157,529
The table presents the cost-effective treatment sequence from Table 4, along with the most cost-effective treatment sequence in a scenario where brodalumab
is not recommended as first-line therapy, and in row 3, the most cost-effective treatment sequence if brodalumab is not recommended in any of the first four
lines of treatment. The cost represents the aggregated costs during the five-year time horizon. The cost of first-, second-, third- and fourth-line therapy repre-
sents the aggregated cost per responder associated with treatment with the therapy in the specific line of treatment.
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risankizumab–brodalumab–guselkumab–ixekizumab
(RIS–BRO–GUS–IXE) represented the 82th ranked treatment
sequence and would have an incremental cost per responder of
e10,333 over the five-year time horizon relative to the most cost-
effective treatment sequence. This corresponded to a cost
increase of 7.42% and a total cost per responder of e149,616.
Finally, row 3 of Table 5 presents the optimal treatment
sequence if brodalumab was not recommended as any of
the first four lines of treatment, risankizumab–ixekizumab–-
guselkumab–ustekinumab (RIS–IXE–GUS–UST). In this scen-
ario, the total cost per responder during the five-year time
horizon increased by 13.1% relative to the most cost-effect-
ive treatment sequence.
Table 6 presents the estimated cost per responder by
year after treatment initiation and line of therapy for
the most cost-effective treatment sequence, i.e. row 1 in
Table 4 (BRO–RIS–GUS–IXE), and the most cost-effective
treatment when brodalumab was not recommended as
any of the first four lines of therapy (RIS–IXE–GUS–UST), in
row 3 in Table 4. Due to a relatively low cost of brodalu-
mab during induction, the “BRO–RIS–GUS–IXE” treatment
sequence was associated with a cost of e28,691 per
responder during the first year relative to the cost of
e40,131 per responder in the first year for the
“RIS–IXE–GUS–UST” treatment sequence.
In contrast to the first year, the cost per responder associ-
ated with treatment of the remaining patients on first-line
therapy was relatively similar between brodalumab, in the
“BRO–RIS–GUS–IXE” sequence, and risankizumab, in the
“RIS–IXE–GUS–UST” sequence, for the remaining years. The
exception in year 4 was caused by the fact that patients who
are still treated with risankizumab would, due to the dosing
scheme, require five administrations in year 4 as opposed to
four administrations in years 2, 3, and 5.
Finally, from Table 6, it became evident that including a
cost-effective first-line therapy also reduced the cost per
responder associated with treatment of patients who initi-
ated treatment with second-, third-, and fourth-line therapies.
During the five-year time horizon, the costs per responder
associated with treatment of patients in second-, third-, and
fourth-line therapies were reduced by e1,903 when com-
pared with the costs of these treatment lines in a scenario
where brodalumab was not recommended as any of the first
four lines of treatment. This accounted for 10.4% of the
total savings.
Figure 2. Estimated cost per responder per year by line of therapy and treatment sequence (in e). The figure presents the total cost per year by line of therapy for
the “BRO–RIS–GUS–IXE” treatment sequence (brodalumab–risankizumab–guselkumab–ixekizumab) and the “RIS–IXE–GUS–UST” treatment sequence (risankizuma-
b–ixekizumab–guselkumab–ustekinumab). The cost of first-, second-, third- and fourth-line therapy represents the yearly cost per responder associated with treat-
ment with the therapy in the specific treatment line.
Table 6. Estimated cost per responder per year by line of therapy and treat-
ment sequence (in e) for the most cost-effective sequence with and with-
out brodalumab.
1st line 2nd line 3rd line 4th line Total cost
Year 1
BRO–RIS–GUS–IXE 26,219 2,401 70 1 28,691
RIS–IXE–GUS–UST 37,363 2,697 70 1 40,131
Year 2
BRO–RIS–GUS–IXE 21,175 5,550 548 37 27,310
RIS–IXE–GUS–UST 21,409 5,775 548 43 27,776
Year 3
BRO–RIS–GUS–IXE 18,581 7,391 1,305 155 27,432
RIS–IXE–GUS–UST 18,976 7,811 1,305 183 28,276
Year 4
BRO–RIS–GUS–IXE 16,305 8,835 2,200 376 27,716
RIS–IXE–GUS–UST 20,717 9,261 2,200 449 32,628
Year 5
BRO–RIS–GUS–IXE 14,308 9,957 3,161 709 28,134
RIS–IXE–GUS–UST 14,466 10,239 3,161 853 28,719
The table presents the total cost per year by line of therapy for the
“BRO–RIS–GUS–IXE” treatment sequence (brodalumab–risankizumab–guselku-
mab–ixekizumab) and “RIS–IXE–GUS–UST” treatment sequence (risankizuma-
b–ixekizumab–guselkumab–ustekinumab). The cost of first-, second-, third-
and fourth-line therapy represents the yearly cost per responder associated
with treatment of the therapy in the specific treatment line.
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The estimated costs per responder by year after treatment
initiation and line of therapy for the “BRO–RIS–GUS–IXE”
treatment sequence and the “RIS–IXE–GUS–UST” treatment
sequence are graphically presented in Figure 2.
Most cost-effective treatment sequences with an anti-IL-
17 as first-line therapy
Several new biological therapies have been introduced over
the past decades and these have had a major impact on the
disease control of moderate-to-severe plaque psoriasis. One
of the more recent classes of biological treatments are the
anti-IL-17s. This class of therapies consists of secukinumab,
ixekizumab, and brodalumab, approved by the European
Medicines Agency between 2015 and 2017. These therapies
have been shown to be highly efficacious in clinical trials
and are therefore likely to be recommended as first-line
therapies in the future.
Table 7 presents the most cost-effective treatment
sequences when either brodalumab, ixekizumab or secukinu-
mab were included as first-line therapy. Again, the most
cost-effective treatment sequence was the one with brodalu-
mab as first-line treatment. We estimated the cost per
responder for the combination of ixekizumab–brodalumab–-
risankizumab–guselkumab to be e153,883, which corre-
sponded to an increase of 10.5% compared with first-line
treatment with brodalumab. The cost per responder for secu-
kinumab as first-line therapy (secukinumab–brodalumab–ri-
sankizumab–guselkumab) was e182,914 corresponding to an
increase of 31.3%. Figure 3 presents the total cost per year
by year after treatment initiation and line of therapy for each
of the three above-mentioned treatment sequences. Once
again it became evident that most of the savings were real-
ized during the first year of treatment.
Sensitivity analysis
We undertook different sensitivity analyses to assess the
robustness of different model parameters. We assessed how
a change in the cost per responder definition impacted the
outcomes. Specifically, the use of PASI75 and PASI90 meas-
ures was evaluated. Furthermore, we assessed how inclusion
Table 7. Cost-effective treatment sequences where first-line therapy is an IL-17 (in e).
Rank 1st line 2nd line 3rd line 4th line Cost 1st line Cost 2nd line Cost 3rd line Cost 4th line Total cost
1 Brodalumab Risankizumab Guselkumab Ixekizumab 96,588 34,133 7,285 1,277 139,283
121 Ixekizumab Brodalumab Risankizumab Guselkumab 117,440 28,124 7,093 1,226 153,883
497 Secukinumab Brodalumab Risankizumab Guselkumab 146,472 28,124 7,093 1,226 182,914
The table presents the cost-effective treatment sequence from Table 4, along with the most cost-effective treatment sequence if other IL-17 therapies are rec-
ommended as first-line therapy. The cost represents the aggregated costs during the five-year time horizon. The cost of first-, second-, third- and fourth-line
therapy represents the aggregated cost per responder associated with treatment with the therapy in the specific line of treatment.
Figure 3. Estimated cost per responder per year by line of therapy for IL-17 treatment sequences (in e). The figure presents the total cost per year by line of ther-
apy for the “BRO–RIS–GUS–IXE” treatment sequence (brodalumab–risankizumab–guselkumab–ixekizumab), the “IXE-BRO-RIS-GUS” treatment sequence (ixekizu-
mab–brodalumab–risankizumab–guselkumab), and the “SEC-BRO-RIS-GUS” treatment sequence (secukinumab–brodalumab–risankizumab–guselkumab). The cost
of first-, second-, third- and fourth-line therapy represents the yearly cost per responder associated with treatment with the therapy in the specific treatment line.
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of biosimilars and different discontinuation rates impacted
the ranking of the most cost-effective treatment sequence.
Change in definition of cost per responder
In the main analysis, we defined responders of biological
therapy as patients who achieved skin clearance, i.e. PASI100,
by week 52. Often, however, patients with moderate-to-
severe plaque psoriasis are said to respond to a given type
of treatment if PASI75 or PASI90 is achieved. Rows 1 and 2
in Table 8 present the cost-effective treatment sequences
when the definition of cost per responder was based on
PASI75 and PASI90, respectively.
Changing the definition of responders to be based on
PASI75 or PASI90 implied that more weight was put on the
actual cost per patient, since a larger share of patients were
now classified as responders. This caused the most cost-
effective treatment sequences to become brodalumab–ixeki-
zumab–guselkumab–ustekinumab (BRO–IXE–GUS–UST) when
responders were defined as patients who achieved PASI75
after 52 weeks of treatment and brodalumab–ustekinumab–-
certolizumab pegol–ixekizumab (BRO–UST–CER–IXE) when
responders were defined as patients who achieved PASI90
after 52 weeks of treatment.
Including biosimilars
In Spain and many other countries, it is advised to treat
patients with biosimilars as a first-line therapy because these
typically cost less. For many dermatologists, the relevant
choice of treatment occurs after patients have discontinued
on one or more biosimilars. As a sensitivity analysis, we
added the older anti-TNF adalimumab, as this is the by far
most used anti-TNF, to the treatment sequence analysis to
evaluate how this lower-priced product would impact the
ranking of the most cost-effective treatment sequences.
Row 3 of Table 8 reports the optimal treatment sequence
from this analysis. It is seen that the inclusion of adalimumab
in the choice set did not change the optimal treatment
sequence from the baseline analysis and thereby did not
impact the estimated cost per responder. The reason that
adalimumab was not included in the optimal treatment
sequence in our model was due to its lower efficacy, as seen
from Table 3, which implied a high cost per responder.
Change in discontinuation rates
One potential drawback of using observed real-world discon-
tinuation rates is that the study by Yiu et al. provides real-
world discontinuation data for only three of the eight investi-
gated biological therapies and only two of the seven
therapies included in the primary analysis. In order to ensure
that the results are not driven by differences in discontinu-
ation rates between the therapies evaluated in Yiu et al.7
and the remaining therapies included in this analysis, we
have performed a sensitivity analysis where the discontinu-
ation rate is set to 1% for all the included therapies. From
row 4 in Table 8, it is seen that the optimal treatment
sequence as well as the cost per responder do not change
when we carry out this sensitivity analysis. In addition to the
above, we conducted a sensitivity analysis where we defined
the risk of discontinuation from the survival curves published
in Egeberg et al.6,22, which provided real-world data on long-
term safety, efficacy, and drug survival data on anti-IL-12/23
and anti-TNF agents for Danish patients with moderate-to-
severe psoriasis. We found similar results using this definition
of treatment discontinuation.
Discussion
The most cost-effective treatment sequence was
BRO–RIS–GUS–IXE, with a cost per responder of e139,283
during the first five years of treatment. In comparison, if bro-
dalumab was not recommended as first-line therapy, total
costs would increase by 7.4% to e149,616. If brodalumab
was not recommended as any of the first four lines of treat-
ment, total costs would increase by 13.1% to e157,529 rela-
tive to the most cost-effective treatment sequence. We also
compared the three anti-IL17 treatment options (brodalu-
mab, ixekizumab, secukinumab). Among the different anti-IL-
17 treatment options, use of brodalumab as first-line treat-
ment was the most cost-effective option. We undertook sev-
eral sensitivity analyses and found that the model
conclusions to be robust to changes in key
model parameters.
Few studies investigated cost-effectiveness of sequential
biologic therapy. One study investigated treatment sequen-
ces, including ixekizumab, ustekinumab and infliximab treat-
ments, in a UK setting and another study focused on
treatment sequences of adalimumab, etanercept and usteki-
numab by use of real-world evidence from the
Netherlands10,11. The two analyses did not find any signifi-
cant differences among the investigated treatment sequen-
ces in terms of cost-effectiveness.
To date, there are no published treatment sequence mod-
els in psoriasis comparing both the older biologics (TNFs and
IL-12/23) as well as the newer biological treatment options
(IL-17s and IL-23s) and focus has only been on comparing up
to three different treatment options. To our knowledge, the
model presented in this manuscript is the first treatment
sequence model to evaluate the cost-effectiveness of more
than 840 different combinations of currently available
Table 8. Sensitivity analyses.
1st line 2nd line 3rd line 4th line Total cost (e)
Cost per responder defined by PASI75 Brodalumab Ustekinumab Ixekizumab Certolizumab pegol 81,367
Cost per responder defined by PASI90 Brodalumab Ixekizumab Guselkumab Ustekinumab 96,102
Including adalimumab Brodalumab Risankizumab Guselkumab Ixekizumab 139,283
All discontinuation rates set to 1% Brodalumab Risankizumab Guselkumab Ixekizumab 139,281
The table presents the optimal treatment sequence as well as the total cost of the given treatment sequence for each listed sensitivity analysis.
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biological therapies (adalimumab, ustekinumab, secukinu-
mab, ixekizumab, brodalumab, guselkumab, risankizumab
and certolizumab pegol) for patients with moderate-to-
severe plaque psoriasis.
One of the unique features of the model is its ability to
incorporate the risk of treatment discontinuation when
searching for the treatment sequence which maximizes the
cost-effectiveness. One limitation of the model is that real-
world data on drug discontinuation is currently very limited.
The model employs the data from Yiu et al.7, which is based
on BADBIR, a large, ongoing pharmacovigilance registry of
patients with psoriasis in the UK and the Republic of Ireland.
To address this potential limitation, we tested how discon-
tinuation rates of 1% across treatments would impact the
ranking of cost-effectiveness among the different treatment
sequence combinations. Very similar results were achieved.
That said, the sensitivity analysis shows that the discontinu-
ation rates in the model only have very modest effects on
the ranking of cost-effectiveness among different treatment
sequence combinations.
The model was set to search for the most cost-effective
treatment sequences where cost per responder was lowest.
Responders were defined by their expected PASI scores after
52 weeks based on estimates from Yasmeen et al.21 By defin-
ing responders based on a point estimate of the expected
efficacy after 52 weeks, the model implicitly assumed that
the number of responding patients was the same through-
out the analysis period. This was chosen even though effi-
cacy increased over time for several therapies (comparing
PASI in week 16 and week 52), at least during the first year
of treatment. A limitation of the model was that the same
efficacy measure was used to calculate cost per responder in
years 2–5.
In addition to this, since the network meta-analysis per-
formed by Yasmeen et al.21 did not separately report the
results for biologic-experienced and biologic-naive patients,
the model assumed PASI response rates to be independent
of patients’ treatment history.
Naturally, cost and efficacy of therapies constituted the
most important parameters in the model, although many
factors in addition to efficacy and cost must be considered
when considering the optimal therapy23,24. The prices used
for the cost calculations were Spanish ex-factory prices,
excluding VAT, from May 2020. Drug costs vary significantly
across markets and potentially also over time. Therefore, the
results presented in this analysis represented the optimal
combination of treatments in the Spanish market based on
list prices at the time of the analysis (May 2020).
Conclusions
Based on this treatment sequence model, we found that the
biological therapy sequence patients are offered is of import-
ance to maximize the use of limited healthcare resources.
With the analyzed data, brodalumab seems to be the
most advisable option as first-line therapy and would lead to
the most cost-effective treatment sequence options. The
most cost-effective treatment sequence was
BRO–RIS–GUS–IXE. This was the case irrespective of whether
adalimumab biosimilar was included in the treatment
sequence choice set or not. The cost per responder was
e139,283 during the first five years of treatment. In compari-
son, if brodalumab was not recommended as first-line ther-
apy, the total costs would increase by 7.4%. If brodalumab
was not recommended as any of the first four lines of treat-
ment, the total costs would increase by 13.1%. The usage of
sequential models may allow achievement of more efficiency
in the selection of treatments for plaque psoriasis.
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